ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Marth, C; Vergote, I; Scambia, G; Oberaigner, W; Clamp, A; Berger, R; Kurzeder, C; Colombo, N; Vuylsteke, P; Lorusso, D; Hall, M; Renard, V; Pignata, S; Kristeleit, R; Altintas, S; Rustin, G; Wenham, Rm; Mirza, Mr; Fong, Pc; Oza, A; Monk, Bj; Ma, H; Vogl FD, ; Bach, Ba.